Literature DB >> 11673745

Use of the erythromycin breath test for in vivo assessments of cytochrome P4503A activity and dosage individualization.

W L Chiou1, H Y Jeong, T C Wu, C Ma.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11673745

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  5 in total

Review 1.  How important are gender differences in pharmacokinetics?

Authors:  Bernd Meibohm; Ingrid Beierle; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 2.  Pharmacogenetics and pharmacogenomics of anticancer agents.

Authors:  R Stephanie Huang; Mark J Ratain
Journal:  CA Cancer J Clin       Date:  2009 Jan-Feb       Impact factor: 508.702

3.  Comparative performance of oral midazolam clearance and plasma 4β-hydroxycholesterol to explain interindividual variability in tacrolimus clearance.

Authors:  Thomas Vanhove; Hylke de Jonge; Henriëtte de Loor; Pieter Annaert; Ulf Diczfalusy; Dirk R J Kuypers
Journal:  Br J Clin Pharmacol       Date:  2016-09-20       Impact factor: 4.335

4.  Immunization and Drug Metabolizing Enzymes: Focus on Hepatic Cytochrome P450 3A.

Authors:  Kristina Jonsson-Schmunk; Romi Ghose; Maria A Croyle
Journal:  Expert Rev Vaccines       Date:  2021-03-18       Impact factor: 5.217

Review 5.  Potential for improvement of docetaxel-based chemotherapy: a pharmacological review.

Authors:  F K Engels; A Sparreboom; R A A Mathot; J Verweij
Journal:  Br J Cancer       Date:  2005-07-25       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.